Impact of hyperfractionated re-irradiation on quality of life in patients with recurrent or second primary head and neck cancer, a prospective single institutional study

Cecilie Delphin Amdal; Jon Magne Moan; Einar Dale; Ragnhild Sørum Falk; Safora Johansen; Kristin Bjordal

doi:10.1016/j.ctro.2023.100654

Impact of hyperfractionated re-irradiation on quality of life in patients with recurrent or second primary head and neck cancer, a prospective single institutional study

Clin Transl Radiat Oncol. 2023 Jun 22:42:100654. doi: 10.1016/j.ctro.2023.100654. eCollection 2023 Sep.

Authors

Cecilie Delphin Amdal^{1

2}, Jon Magne Moan¹, Einar Dale¹, Ragnhild Sørum Falk², Safora Johansen^{1

3}, Kristin Bjordal^{2

4}

Affiliations

¹ Department of Oncology, Oslo University Hospital, Oslo, Norway.
² Research Support Services, Oslo University Hospital, Oslo, Norway.
³ Oslo Metropolitan University, Faculty of Health Sciences, Oslo, Norway.
⁴ University of Oslo, Faculty of Medicine, Oslo, Norway.

Abstract

Purpose: Describe the clinical outcome of hyperfractionated re-irradiation (HFRT) in patients with recurrent or second primary (SP) head and neck cancer (HNC).

Methods: This prospective observational study included HNC patients eligible for HFRT. Inclusion criteria: age ≥18 years, recurrent or SP HNC, planned re-irradiation and ability to respond to questionnaires. Patients received 1.5 Gy twice daily, five days a week for three (palliative) or four (curative/local control) weeks, total dose 45/60 Gy. Toxicity was scored with CTCAE v3 at baseline, end of treatment, at three, six, 12 and 36 months follow-up. Health-related quality of life (HRQoL) was measured with EORTC QLQ-C30 and EORTC QLQ-H&N35, pre-treatment and eight times until 36 months. In the main outcome (Global quality of life and H&N Pain), a change score of ≥10 was considered clinically significant, and p-values < 0.05 (two-sided) statistically significant. The Kaplan-Meier method was used for survival analyses.

Results: Over four years from 2015, 58 patients were enrolled (37 recurrent and 21 SP). All, but two patients completed treatment as planned. Toxicity (≥grade 3) increased from pre-treatment to end of treatment with improvement in the follow-up period. The mean Global quality of life (QoL) and H&N Pain scores were stable from pre-treatment to three months. Maintained/ improved Global QoL was reported by 60% of patients at three months and 56% of patients at 12 months. For patients with curative, local control and palliative intent, the median survival (range) was 23 (2-53), 10 (1-66) and 14 (3-41) months respectively. Of those alive, the proportion of disease-free patients at 12 and 36 months, were 58% and 48%, respectively.

Conclusion: Most HNC patients reported maintained HRQoL at three and 12 months after HFRT despite serious toxicity observed in many patients. Long-term survival can be achieved in a limited proportion of the patients.

Keywords: Head and neck cancer; Health-related quality of life; Patient-reported outcome measure; Radiotherapy; Recurrent disease.